Dr. Kline is a medical oncologist who specializes in the treatment of patients with Hodgkin and non-Hodgkin lymphoma, including stem cell transplantation and CAR T cell therapy. He has expertise in the development and use of immunotherapy, and his lab research is focused on overcoming immune evasion pathways activated in blood cancers and on improving the effectiveness of immune-based treatments for people with lymphoma.
University of Chicago
Chicago
- Hematology/Oncology
2007University of Chicago
Chicago
- Internal medicine
2004University of Chicago
Chicago
M.D. - Medicine
2001Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025 May 22; 145(21):2460-2472.
PMID: 39869833Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy.
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy. bioRxiv. 2025 May 20.
PMID: 40463198Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma.
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205.
PMID: 40328775Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma.
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma. bioRxiv. 2025 Mar 15.
PMID: 40161759FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients.
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49.
PMID: 38911560A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
PMID: 37851072Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
PMID: 37827881TIGIT is a key inhibitory checkpoint receptor in lymphoma.
TIGIT is a key inhibitory checkpoint receptor in lymphoma. J Immunother Cancer. 2023 06; 11(6).
PMID: 37364933A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
PMID: 35851593Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents.
View All Publications
Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents. Matter. 2021 Dec 01; 4(12):3917-3940.
PMID: 34901832